Shire to acquire New River in $2.6 billion deal

Share this article:
British drugmaker Shire said today it has agreed to buy New River Pharmaceuticals for $2.6 billion or $64 a share in cash. Shire said in published reports the deal will allow the company to capture the full economic value of attention deficit hyperactivity disorder (ADHD) drug Vyvanse and to gain control of the future development and commercialization of the treatment. Shire said the acquisition is in line with its increased focus on the ADHD market. “This is an important and complementary acquisition that gives us full control of Vyvanse, a novel drug,” Shire CEO Matthew Emmens said in a statement. Emmens added that he expects the purchase to add to earnings from late 2009. New River developed Vyvanse, a follow-on ADHD drug that Shire is hoping will replace Adderall, which accounted for more than half of Shire’s third-quarter sales. In January 2005, Shire and New River struck a collaborative agreement to develop and co-promote Vyvanse.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...